A comparative study of the efficacy and tolerance of three antiglaucoma prostaglandin analogue eyedrops (Latanoprost, Travoprost and Bimatoprost)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN91423473

Enrollment

120

Registered

2003-09-12

Start date

2003-02-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Eye Diseases: Glaucoma Eye Diseases Glaucoma

Interventions

1. Latanoprost 2. Travoprost 3. Bimatoprost

Eligibility

Inclusion criteria

Inclusion criteria: Added March 2008: Newly diagnosed patients with ocular hypertension, open angle glaucoma (including primary open angle glaucoma, pseudo-exfoliation and pigment dispersion syndrome) or normal tension glaucoma.

Exclusion criteria

Exclusion criteria: Added March 2008: 1. Patients <20 years 2. Pregnancy 3. Intraocular pressure (IOP) of 40 mmHg or more 4. Severe visual field loss or scotoma within 5° of fixation 5. Patients with secondary glaucoma 5. History of intraocular surgery in the preceding year 6. Prostaglandin derivative was contraindicated

Design outcomes

Primary

Measure	Time frame
Added March 2008: A comparison of the efficacy, in terms of intra-ocular pressure reduction.	—

Secondary

Measure	Time frame
Added March 2008: A comparison of the tolerance profile.	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026